Patients with higher tumor VEGF121 mRNA levels
Patients with higher tumor VEGF121 mRNA levels have a significantly shorter [url=http://www.selleckchem.com/products/AZD6244.html]AZD6244[/url] survival compared with those having lower grades suggesting that angiogenic activity may be up-regulated in tumors with a high ability to invade. Thereby, patients with high soluble VEGF levels can have a more aggressive disease, and the improved outcome observed in our series might be a reflection of disease the field of biology.It is hard to speculate at this [url=http://www.selleckchem.com/products/AZD6244.html]Selumetinib[/url] point on why the association of survival is way better with the ratio involving VEGF121/VEGF165 than with VEGF121 alone. However, we have previously shown that VEGF121 is the most expressed isoform with RCC. Tomisawa et al have also shown that VEGF121 is more expressed than VEGF165 and VEGF189 and while all the analyzed RCC principal tumors expressed VEGF121, only 70% showed expression with VEGF165. [url=http://www.selleckchem.com/products/XL880(GSK1363089,EXEL-2880).html]xl880[/url] In addition, these authors report that neither VEGF165 nor VEGF189 have been expressed alone in RCCs. It is worth noting that ratio avoids the utilization of housekeeping genes and would probably thus provide a more user-friendly and uncomplicated clinical test.Therefore, if these new drugs supply considerable promise for patients, there is a crucial require for a better selection with patients. Indeed, tumors [url=http://www.selleckchem.com/products/AZD2281(Olaparib).html]AZD2281[/url] with close characteristics can present opposite behavior with either important and long regressions, and very short-term progressions. TKI are generally multikinase inhibitors, which impact a broad cascade of signaling path ways. Thereby, the optimization of their efficiency will be based upon a correlation between reaction to treatment and individual tumor signatures.In conclusion, this preliminary study constitutes a first step in [url=http://www.selleckchem.com/products/ABT-263.html]ABT-263 [/url] that identification of surrogate biomarkers associated with sunitinib antiangiogenic activity within mRCC and requires confirmation in a larger independent series with patients. Indeed, tumor soluble VEGF mRNA represents a potentially promising tool that will help the clinician to recognize patients who might benefit from sunitinib avoiding a costly and potentially toxic administration of this treatment in non-responding patients.

Latest Comments